Abstract
Vaccines adjuvants are critically needed to enhance the effectiveness of subunit vaccines. Due to their ability to link the innate with the adaptive immune response, Toll-like receptor (TLR) agonists have received great attention as adjuvants in vaccines against severe and complex diseases such as cancer, AIDS, and malaria. Here, we describe in vitro assays, e.g., the Monocyte Activation Test, TLR-specific activation assay, and TLR-blocking experiments, used to assess TLR agonists adjuvanted vaccines’ safety and to characterize their ability to stimulate the innate immunity. Such assays are physiologically relevant as they work with human cells and allow to overcome the complexity and variability related to in vivo assays.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Luchner M, Reinke S, Milicic A (2021) TLR agonists as vaccine adjuvants targeting cancer and infectious diseases. Pharmaceutics 13(2):142
Vasilakos J, Tomai M (2012) TLR agonists as vaccine adjuvants. In: Baschieri S (ed) Innovation in vaccinology: from design, through to delivery and testing. Springer, Dordrecht, pp 205–228. https://doi.org/10.1007/978-94-007-4543-8_9
Jin MS, Lee JO (2008) Structures of TLR-ligand complexes. Curr Opin Immunol 20(4):414–419. https://doi.org/10.1016/j.coi.2008.06.002
Rossi O, Citiulo F, Mancini F (2021) Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans. Hum Vaccin Immunother 17(2):601–613. https://doi.org/10.1080/21645515.2020.1780092
Valentini S, Santoro G, Baffetta F, Franceschi S, Paludi M, Brandini E, Gherardini L, Serruto D, Capecchi B (2019) Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: an in vitro pyrogen test to overcome in vivo limitations. Vaccine 37(29):3754–3760. https://doi.org/10.1016/j.vaccine.2018.10.082
Mancini F, Rossi O, Necchi F, Micoli F (2020) OMV vaccines and the role of TLR agonists in immune response. Int J Mol Sci 21(12):4416
Flecknell P (2002) Replacement, reduction and refinement. ALTEX 19(2):73–78
Carson D, Myhill S, Palmieri E, Necchi F, Rijpkema S, Micoli F, Nordgren IK, Rossi O, Vipond C (2021) Development of a monocyte activation test as an alternative to the rabbit pyrogen test for mono- and multi-component shigella GMMA-based vaccines. Microorganisms 9(7). https://doi.org/10.3390/microorganisms9071375
Conflict of Interest
All authors were involved in drafting the book chapter and approved the final version. This work was sponsored by GlaxoSmithKline Biologicals SA. The authors declare the following interests: FMa, FMi, and OR are employees of the GSK group of companies. GVGH is an affiliate of GlaxoSmithKline Biologicals SA.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Mancini, F., Micoli, F., Rossi, O. (2023). Study of Agonists of TLRs as Vaccine Adjuvants. In: Fallarino, F., Gargaro, M., Manni, G. (eds) Toll-Like Receptors. Methods in Molecular Biology, vol 2700. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3366-3_15
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3366-3_15
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3365-6
Online ISBN: 978-1-0716-3366-3
eBook Packages: Springer Protocols